Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Specht E, Pakanati L, Wu MJ, Jenkins RW, Effiom DN, Bardeesy N, Bernstein BE, Sade-Feldman M, Lian CG, Boland GM, Torlai Triglia E, Cohen S. Loss of tumor-infiltrating lymphocytes and poor response to immunotherapy in IDH GOF mutant melanoma. JCI Insight. 2026 Jun 08; 11(11).
-
Fernando W, Clucas J, Rizzo A, Singer R, Goode E, Tiu C, Layzell S, Konecnik J, Wilson R, Wicky John S, Jouny S, Guppy N, Boulat V, Mannion J, Goicoechea M, Tan S, Lawson S, Starling C, Elshtein G, Ravindran N, Montgomery AB, Andres-Ejarque R, Allen M, Lumbard S, Wallberg F, Betteridge K, Scrimgeour R, Robertson D, Ward G, Sims M, Smyth T, Samson AL, Murphy JM, Kolarevic Ivankovic D, Arwert EN, Calado DP, Grigoriadis A, Smalley MJ, Melcher A, Haider S, Lawrence T, Roxanis I, Tutt ANJ, Tenev T, Meier P. Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy. Nat Commun. 2026 Mar 06; 17(1).
-
Zhan X, Xiao H, Wang Q, Luo J, Ma L, Zhang X, Tang J, Meng X. Natural killer cell nano-engagers drive ferroptosis-immunomodulation synergy via inhibition of the Interleukin-6-JAK2-STAT3 Axis. J Control Release. 2026 Feb 10; 390:114581.
-
Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, Hungria V, Zamagni E. Extramedullary Disease-Achilles Heel in Myeloma? Am J Hematol. 2026 03; 101(3):521-536.
-
Sun JX, Ma SY, Xu JY, Abudureyimu M, An Y, Xu JZ, Zhang SH, Zhang ZY, Guo CX, Liu BL, Wang SG, Xia QD. Escherichia coli Nissle 1917 outer membrane vesicles encapsulating oncolytic virus remodel tumor-associated macrophages and kill prostate cancer cells. J Control Release. 2026 Feb 10; 390:114514.
-
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.
-
Murphy KC, DeMarco KD, Zhou L, Peura J, Giwa HK, Lopez-Diaz Y, Ho YJ, Li J, Bai S, Simin K, Zhu LJ, Pitarresi JR, Mercurio AM, Ruscetti M. MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T-cell and Immunotherapy Responses in Prostate Cancer. Cancer Res. 2025 Nov 14; 85(22):4359-4379.
-
Sarkar S, Chang CI, Jean J, Wu MJ. TCA cycle-derived oncometabolites in cancer and the immune microenvironment. J Biomed Sci. 2025 Sep 10; 32(1):87.
-
Skelly DA, Graham JP, Cheng M, Furuta M, Walter A, Stoklasek TA, Yang H, Stearns TM, Poirion O, Zhang JG, Grassmann JDS, Luo D, Flynn WF, Courtois ET, Chang CH, Serreze DV, Menghi F, Reinholdt LG, Liu ET. Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response. Cell Rep. 2025 May 27; 44(5):115698.
-
Huang Z, Li Y, Bucci V, Haran JP. Decoding cancer prognosis with deep learning: the ASD-cancer framework for tumor microenvironment analysis. mSystems. 2025 May 20; 10(5):e0145524.